For patients with advanced basal cell carcinoma (BCC) not curable by surgery, combining targeted drug therapy with radiation offers strong tumor control and long-term benefits. The drug (a Hedgehog pathway inhibitor like vismodegib) shrinks tumors and makes them more sensitive to radiation, while radiation destroys remaining cancer cells.
A Phase II trial in patients with head and neck BCC showed a 91% tumor control rate at one year, 83% overall response, and 78% progression-free survival at five years. Patients also reported better quality of life.
This approach reduces the need for disfiguring surgery, offers high cure rates, and improves outcomes for patients with difficult-to-treat tumors.